I feel partnering would be more in the interests of the board no? FDA approval is a tough task, especially for an Aussie Biotech. The drug clearly works, but the politics could stretch it? If PAR are gunning for an OA partnership now it would make sense that they take more to partnering off the paediatric orphan MPS designation.
I say this because Paul Rennie was the inaugural COO of Mesoblast and Executive VP, New Product Development at Mesoblast Ltd.
Dr. Skerrett was the CMO of Mesoblast too (2011-2019). We all know all the dramas Mesoblast experienced chasing FDA approval in what many thought was a sure thing.
I feel partnering would be more in the interests of the board...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.020(8.51%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 26.5¢ | 23.5¢ | $263.5K | 1.057M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 155790 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 80000 | 2 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
0.020 ( 6.38 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 26.5¢ | 23.5¢ | 218514 | ||
| Last updated 15.58pm 07/05/2024 ? | |||||
| PAR (ASX) Chart |